Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

659 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience.
Mohan M, Becnel MR, Shah UA, Dong H, Gundarlapalli S, Peterson T, Orozco JS, Horowitz S, Chhabra S, Dhakal B, Thanendrarajan S, Radhakrishnan SV, Al Hadidi S, Tan C, Mailankody S, Hultcrantz M, Korde N, Hassoun H, Lesokhin AM, Thomas SK, Patel KK, Manasanch EE, Weber DM, Szabo A, Kaufman GP, Lee HC, Zangari M, van Rhee F, Usmani SZ, D'Souza A, Orlowski RZ, Schinke C. Mohan M, et al. Among authors: horowitz s. Am J Hematol. 2022 Jul;97(7):E276-E280. doi: 10.1002/ajh.26580. Epub 2022 May 2. Am J Hematol. 2022. PMID: 35472167 Free PMC article. No abstract available.
Hyperfractionated Cyclophosphamide and Dexamethasone Alone or in Combination with Daratumumab and/or Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma: A Single-Center Retrospective Analysis.
Shank BR, Primeaux B, Yeung EK, Horowitz SB, Lee IY, Roccograndi L, Feng L, Kaufman GP, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Weber DM, Becnel MR, Thomas SK. Shank BR, et al. Among authors: horowitz sb. Clin Lymphoma Myeloma Leuk. 2023 Apr;23(4):279-290. doi: 10.1016/j.clml.2022.12.004. Epub 2022 Dec 10. Clin Lymphoma Myeloma Leuk. 2023. PMID: 36797154 Free PMC article.
A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.
Strati P, Chihara D, Oki Y, Fayad LE, Fowler N, Nastoupil L, Romaguera JE, Samaniego F, Garg N, Feng L, Wesson ET, Ruben CE, Stafford MD, Nieto Y, Khouri IF, Hosing C, Horowitz SB, Kamble RT, Fanale MA. Strati P, et al. Haematologica. 2018 Sep;103(9):e416-e418. doi: 10.3324/haematol.2018.187617. Epub 2018 Apr 5. Haematologica. 2018. PMID: 29622656 Free PMC article. Clinical Trial. No abstract available.
Ifosfamide, carboplatin, etoposide with or without bortezomib in patients with relapsed/refractory Hodgkin lymphoma: results of a randomized phase II trial.
Karuturi M, Younes A, Fayad L, Kwak L, Pro B, Shah J, Oki Y, Simien R, Liboon MJ, Hutto T, Feng L, Horowitz S, Nieto Y, Anderlini P, Alousi A, Popat U, Medeiros LJ, Miranda R, Fanale M. Karuturi M, et al. Among authors: horowitz s. Leuk Lymphoma. 2016 Feb;57(2):445-447. doi: 10.3109/10428194.2015.1032966. Epub 2015 Mar 25. Leuk Lymphoma. 2016. PMID: 25804933 Free PMC article. No abstract available.
Chimeric Antigen Receptor T Cells in Hematologic Malignancies.
Shank BR, Do B, Sevin A, Chen SE, Neelapu SS, Horowitz SB. Shank BR, et al. Among authors: horowitz sb. Pharmacotherapy. 2017 Mar;37(3):334-345. doi: 10.1002/phar.1900. Epub 2017 Feb 22. Pharmacotherapy. 2017. PMID: 28079265 Review.
Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma.
Fanale MA, Cheah CY, Rich A, Medeiros LJ, Lai CM, Oki Y, Romaguera JE, Fayad LE, Hagemeister FB, Samaniego F, Rodriguez MA, Neelapu SS, Lee HJ, Nastoupil L, Fowler NH, Turturro F, Westin JR, Wang ML, McLaughlin P, Pinnix CC, Milgrom SA, Dabaja B, Horowitz SB, Younes A. Fanale MA, et al. Among authors: horowitz sb. Blood. 2017 Jul 27;130(4):472-477. doi: 10.1182/blood-2017-02-766121. Epub 2017 May 18. Blood. 2017. PMID: 28522441 Free PMC article. Clinical Trial.
Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma.
Strati P, Ahmed S, Kebriaei P, Nastoupil LJ, Claussen CM, Watson G, Horowitz SB, Brown ART, Do B, Rodriguez MA, Nair R, Shpall EJ, Green MR, Neelapu SS, Westin JR. Strati P, et al. Among authors: horowitz sb. Blood Adv. 2020 Jul 14;4(13):3123-3127. doi: 10.1182/bloodadvances.2020002328. Blood Adv. 2020. PMID: 32645136 Free PMC article. No abstract available.
659 results